The von-Hippel-Lindau (VHL) tumor suppressor gene is not mutated in sporadic ovarian carcinomas

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 887-890

  Nakashima, Ryuichi ^a   Enomoto, Takayuki ^a   Fujita, Masami ^a   Yoshino, Kiyoshi ^a   Wada, Hiroko ^a   Kondo, Keiichi ^b   Yao, Masahiro ^b   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

ovarian carcinoma; tumor suppressor gene; VHL

Indexed keywords

DNA;

ARTICLE; CARCINOGENESIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0029811788     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.5.887     Document Type: Article

References (38)

1. Fearon E and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
2. Enomoto T, Weghorst CM, Inoue M, Tanizawa O and Rice JM: K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-785, 1991.
3. Fujita M, Enomoto T, Inpue M, Ozaki M, Rice JM, Nomura T and Tanizawa O: Alteration of the p53 tumor suppressor gene occurs more frequently in serous adenocarcinomas than other common epithelial tumors of the human ovary. Jpn J Cancer Res 85: 1247-1256, 1994.
4. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
6. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M and Yokota J: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176, 1991.
7. Mazars R, Pujol P, Maudelonde T, Jcantcur P and Theillet C: p53 mutations in ovarian cancer: a late event? Oncogene 6: 1685-1690, 1991.
8. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast Jr RC and Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519, 1993.
9. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT and Blick M: Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 50: 2724-2728, 1990.
10. Ehlen T and Dubeau L: Loss of heterozygosity on chromosomal segments 3p, 6q, and 11p in human ovarian carcinomas. Oncogene 5: 219-223, 1990.
11. Sato T, Saito H, Morita R, Koi S, Lee JH and Nakamura Y: Allelotype of human ovarian cancer. Cancer Res 51: 5118-5122, 1991.
12. Li S, Shwartz PE, Lee W-H and Yang-Feng TL: Allelic loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst 83: 637-640, 1991.
13. Enomoto T, Fujita M, Cheng C, Nakashima R, Ozaki M, Inoue M and Nomura T: Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 71: 462-467, 1995.
14. Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, Inoue M and Okudaira Y: Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64: 361-366, 1995.
15. Latif F, Tory K, Gnana J, Yao M, Duh F-M, Orcutt ML, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320, 1993.
16. Kuzmin I, Duh FM, Latif F, Geil L, Zbar B and Lerman MI: Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10: 2185-2194, 1995.
17. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, et al: Germ-line mutations in the von Hippel-Lindau disease tumor suppressor gene: correlation with phenotype. Hum Mutat 5: 66-75, 1995.
18. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994.
19. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 7: 85-90, 1994.
20. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T and Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54: 4845-4847, 1994.
21. Chen F, Kishida T, Duh F-M, Renbaum P, Orcutt ML, Schmidt L and Zbar B: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55: 4804-4807, 1995.
22. Iliopoulos O, Kibel A, Gray S and Kaelin WG Jr: Tumor suppression by the human von Hippel-Lindau gene product. Nature Med 1: 822-826, 1995.
23. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM and Klausner RD: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406, 1995.
24. Kibel A, Iliopoulos O, DeCaprio JA and Kaelin WJ Jr: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446, 1995.
25. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O and Rice JM: K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 50: 6139-6145, 1990.
26. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI and Minna JD: Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9: 1599-1604, 1994.
27. Sun Y, Hildesheim A, Li H, Lanier AP, Cao Y, Yao KT, Yang CS and Colburn NH: The von Hippel-Lindau (VHL) disease tumor suppressor gene is not mutated in nasopharyngeal carcinomas. Int J Cancer 61: 437-438, 1995.
28. Schiller W: Mesonephroma ovarii. Am J Cancer 35: 1-21, 1939.
29. Scully RE and Barlos JF: 'Mesonephroma' of the ovary: Tumor of Müllerian nature related to endometrioid cacinoma. Cancer 20: 1405-1417, 1967.
30. Genton CY: Ultrastructure of clear cell carcinoma of the ovary. Case report and review of the literature. Virchows Arch (A) 385: 77-91, 1979.
31. Ohkawa K, Amasaki H, Terashima Y, Aizawa S and Ishikawa E: Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 40: 3019-3029, 1977.
32. Lash RH and Hart WR: Intestinal adenocarcinomas metastatic to the ovaries: a clinicopathologic evaluation of 22 cases. Am J Surg Pathol 11: 114-121, 1987.
33. Young RH and Hart WR: Metastasis from carcinomas of the pancreas simulating primary mucinous tumors of the ovary: a report of seven cases. Am J Surg Pathol 13: 748-756, 1989.
34. Young RH, Gilks CB and Scully RE: Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 15: 415-429, 1991.
35. Spencer JR, Eriksen B and Garnett JE: Metastatic renal tumor presenting as ovarian clear cell carcinoma. Urology 41: 582-584, 1993.
36. Young RH and Hart WR: Renal cell carcinoma metastatic to the ovary: a report of three cases emphasizing possible confusion with ovarian clear cell adenocarcinoma. Int J Gynecol Pathol 11: 96-104, 1992.
37. Pinkus GS and Kurtin PJ: Epithelial membrane antigen - a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 16: 929-940, 1985.
38. Wick MR, Chervitz DL, Manivel JC and Sibley R: Tumors and tumor-like conditions of the kidneys and ureters. In: Contemporary Issues in Surgical Pathology. Eble JN (ed). Vol. 16. Churchill Livingstone, New York, pp207-247, 1990.